Overall survival and progression-free survival are the primary endpoints of the trial. Credit: Yale Rosen.

Innovent Biologics has reported positive interim analysis results from Phase III ORIENT-32 study of anti-PD-1 antibody-based combination therapy versus sorafenib for treating patients with advanced unresectable hepatocellular carcinoma (HCC).

The combination therapy includes TYVYT (sintilimab injection) and BYVASDA (bevacizumab biosimilar injection).

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

TYVYT is an immunoglobulin G4 monoclonal antibody that attaches to PD-1 molecules present on the T-cells. It inhibits the PD-1/ PD-Ligand 1 pathway and reactivates T-cells to destroy cancer cells.

BYVASDA is a recombinant humanised anti-VEGF monoclonal antibody drug.

The randomised, open-label, multi-centre study is analysing the efficacy and safety of TYVYT plus BYVASDA compared to sorafenib in HCC patients.

The study enrolled 571 patients who were randomly given TYVYT plus BYVASDA or sorafenib, until disease progression, unacceptable toxicity, withdrawal of consent, death, or other reasons.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Overall survival (OS) and progression-free survival (PFS) are the primary endpoints of the trial.

Data from the interim analysis by the study’s independent data monitoring committee (IDMC) showed that the combination of both demonstrated significantly improved OS and Independent Radiographic Review Committee (IRRC) PFS versus sorafenib.

The combination therapy showed a 43.1% decreased risk of all-cause mortality as compared to sorafenib. Moreover, it showed a 43.5% decreased risk of progression as assessed by IRRC.

An acceptable safety profile of the therapy was also noted during the trial, with no new safety signals observed.

Innovent Oncology Strategy and Medical Sciences vice-president and head Dr Hui Zhou: “With these encouraging results, we will apply to the National Medical Products Administration for the new drug application of TYVYT (sintilimab injection) in combination with BYVASDA (bevacizumab biosimilar injection).

“We look forward to this potentially becoming a new treatment regimen that could help more patients with HCC to live longer without their disease worsening.”